{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:29:18Z","timestamp":1787236158794,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":6164,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1093\/annonc\/mdg078","type":"journal-article","created":{"date-parts":[[2003,2,3]],"date-time":"2003-02-03T16:06:47Z","timestamp":1044288407000},"page":"197-204","source":"Crossref","is-referenced-by-count":38,"title":["Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"C.M.F.","family":"Kruijtzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Boot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.L.","family":"Lochs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.X.","family":"Parnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.T.","family":"Planting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.G.","family":"Pelgrims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.A.","family":"Math\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Schot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"van Tinteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdg078_bb0010","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.1994.12.2.412","article-title":"Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer","volume":"12","author":"Cullinan","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg078_bb0015","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/JCO.1991.9.5.827","article-title":"Sequential high-dose methotrexate and fluorouracil combined with doxorubicin. A step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group","volume":"9","author":"Wils","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg078_bb0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO.1997.15.1.261","article-title":"Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer","volume":"15","author":"Webb","year":"1997","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1093\/annonc\/mdg078_bb0025","first-page":"A-601","article-title":"Epirubicin, cisplatin and continuous 5-FU chemotherapy (ECF-regimen) in patients with cancer of the gastroesophageal junction and stomach","volume":"122","author":"Boot","year":"2002","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1093\/annonc\/mdg078_bb0030","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00000421-199808000-00021","article-title":"An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer","author":"Ohtsu","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdg078_bb0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00001813-199804000-00003","article-title":"Phase II study of paclitaxel in pretreated advanced gastric cancer","volume":"9","author":"Cascinu","year":"1998","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1093\/annonc\/mdg078_bb0040","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00873804","article-title":"Phase II trial of Taxol in patients with adenocarcinoma of upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology Group (ECOG) results","author":"Einzig","year":"1995","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdg078_bb0045","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1023\/A:1011680507956","article-title":"Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions","volume":"12","author":"Yamada","year":"2001","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdg078_bb0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00001813-199507004-00005","article-title":"Docetaxel delivers new management opportunities for gastrointestinal carcinomas","volume":"6","author":"Rougier","year":"1995","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdg078_bb0055","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1200\/JCO.1997.15.3.901","article-title":"Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study","volume":"15","author":"Safran","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg078_bb0060","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/00001813-199704000-00014","article-title":"Phase II trial of paclitaxel and weekly 24 hour infusion of 5-fluorouracil\/folinic acid in patients with advanced gastric cancer","volume":"8","author":"Bokemeyer","year":"1997","journal-title":"Anticancer Drugs"},{"issue":"4","key":"10.1093\/annonc\/mdg078_bb0065","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1054\/bjoc.2000.1295","article-title":"A phase II study of paclitaxel, weekly 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer","author":"Kollmannsberger","year":"2000","journal-title":"Br J Cancer"},{"issue":"Suppl 19","key":"10.1093\/annonc\/mdg078_bb0070","first-page":"86","article-title":"A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer","volume":"24","author":"Philip","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg078_bb0075","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.1998.16.10.3353","article-title":"Dose dense therapy with weekly 1 hour paclitaxel infusions in metastatic breast cancer","volume":"16","author":"Seidman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg078_bb0080","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO.1998.16.1.153","article-title":"Phase I trial of weekly paclitaxel in advanced lung cancer","volume":"16","author":"Akerley","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg078_bb0085","article-title":"CALGB 9731: phase II study of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC)","author":"Akerley","year":"1783","journal-title":"Proc Am Soc Clin Oncol1999; 18: 462a (Abstr"},{"key":"10.1093\/annonc\/mdg078_bb0090","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.94.5.2031","article-title":"Limited oral bioavailability and active epithelial excretion of paclitaxel caused by P-glycoprotein in the intestine","volume":"94","author":"Sparreboom","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdg078_bb0095","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1010635000879","article-title":"Oral delivery of taxanes","volume":"19","author":"Malingr\u00e9","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdg078_bb0100","first-page":"2293","article-title":"Enhanced oral absorption and decreased elimination of paclitaxel in mice co-treated with cyclosporin A","volume":"4","author":"van Asperen","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdg078_bb0105","first-page":"3379","article-title":"Malingr\u00e9 MM, Beijnen JH et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel","volume":"5","author":"Meerum Terwogt","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdg078_bb0110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00001813-200104000-00008","article-title":"The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel","volume":"12","author":"Malingr\u00e9","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdg078_bb0115","first-page":"235","article-title":"Cytotoxic studies of paclitaxel in human tumour cell lines","volume":"32","author":"Liebmann","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdg078_bb0120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00001813-199704000-00011","article-title":"Effects of prolonged versus short-term exposure paclitaxel on human tumor colony-forming units","volume":"8","author":"Raymond","year":"1997","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdg078_bb0125","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s002800000226","article-title":"A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A","volume":"47","author":"Malingr\u00e9","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdg078_bb0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdg078_bb0135","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1200\/JCO.2000.18.12.2468","article-title":"A Phase I and pharmacokinetic study of paclitaxel","volume":"18","author":"Malingr\u00e9","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg078_bb0140","series-title":"Guidelines for Reporting of Adverse Drug Reactions","year":"1998"},{"key":"10.1093\/annonc\/mdg078_bb0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0378-4347(95)00308-8","article-title":"Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography","volume":"674","author":"Huizing","year":"1995","journal-title":"J Chromatogr B Biomed Appl"},{"key":"10.1093\/annonc\/mdg078_bb0150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00007691-199202000-00007","article-title":"Relative performance of specific and nonspecific fluorescence polarization immunoassay for cyclosporin in transplant patients","volume":"14","author":"Chan","year":"1992","journal-title":"Ther Drug Monit"},{"key":"10.1093\/annonc\/mdg078_bb0155","series-title":"NONMEM Users guide Part VI: PREDPP guide","author":"Beal","year":"1992"},{"key":"10.1093\/annonc\/mdg078_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mdg078_bb0165","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/07357909509031919","article-title":"Taxanes: a new class of antitumor agents","volume":"13","author":"Huizing","year":"1995","journal-title":"Cancer Invest"},{"key":"10.1093\/annonc\/mdg078_bb0170","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.1997.15.1.317","article-title":"Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients","volume":"15","author":"Huizing","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg078_bb0175","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2002.04.058","article-title":"Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer","volume":"20","author":"Kruijtzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg078_bb0180","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.1995.13.1.180","article-title":"Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic\/pharmacodynamic relationships in humans","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419453544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419453544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/14\/2\/197\/361687\/mdg078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T01:53:22Z","timestamp":1582163602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419453544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["S0923753419453544"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdg078","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}